Open Access

Clinical significance of plasma metastin level in pancreatic cancer patients

  • Authors:
    • Fumihiko Katagiri
    • Kazuyuki Nagai
    • Atsushi Kida
    • Kenji Tomita
    • Shinya Oishi
    • Masaharu Takeyama
    • Ryuichiro Doi
    • Nobutaka Fujii
  • View Affiliations

  • Published online on: March 1, 2009     https://doi.org/10.3892/or_00000289
  • Pages: 815-819
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Metastin, which is a 54-residue peptide coded by KiSS-1 gene, is an endogenous ligand to a G-protein-coupled receptor GPR54. Metastin suppresses a malignant tumor to metastasize and regulates secretion of gonadotropine releasing hormone. Physiological action of metastin has been focused on in oncology. It is reported that less KiSS-1 gene and more hOT7T175 gene which codes GPR54 are expressed in pancreatic cancers than in normal pancreatic tissues; however, there is no study that investigates the relationship between clinicopathological characteristics and plasma metastin concentration in pancreatic cancer patients. The purpose of this study was to investigate the relationship between plasma metastin-like immunoreactive substance (LI) levels and clinical characteristics in pancreatic cancer patients. Thirty-three patients with pathologically confirmed pancreatic cancer before or just after treatments and 24 healthy volunteers were included in the study. Patients were grouped according to the International Union Against Cancer TNM classification. Plasma metastin-LI was measured by enzyme immunoassay. The plasma metastin-LI levels of cancer patients were significantly higher when compared with healthy volunteers. Significant relationship was not found between the plasma metastin-LI levels and the clinicopathological factors such as tumor size, invasion, lymph node metastasis and distant metastasis. The plasma metastin levels may be a significant biomarker to predict the presence of pancreatic cancer and could be used in pancreatic cancer screening.

Related Articles

Journal Cover

March 2009
Volume 21 Issue 3

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Katagiri F, Nagai K, Kida A, Tomita K, Oishi S, Takeyama M, Doi R and Fujii N: Clinical significance of plasma metastin level in pancreatic cancer patients. Oncol Rep 21: 815-819, 2009
APA
Katagiri, F., Nagai, K., Kida, A., Tomita, K., Oishi, S., Takeyama, M. ... Fujii, N. (2009). Clinical significance of plasma metastin level in pancreatic cancer patients. Oncology Reports, 21, 815-819. https://doi.org/10.3892/or_00000289
MLA
Katagiri, F., Nagai, K., Kida, A., Tomita, K., Oishi, S., Takeyama, M., Doi, R., Fujii, N."Clinical significance of plasma metastin level in pancreatic cancer patients". Oncology Reports 21.3 (2009): 815-819.
Chicago
Katagiri, F., Nagai, K., Kida, A., Tomita, K., Oishi, S., Takeyama, M., Doi, R., Fujii, N."Clinical significance of plasma metastin level in pancreatic cancer patients". Oncology Reports 21, no. 3 (2009): 815-819. https://doi.org/10.3892/or_00000289